secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001437749-24-027380
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree Q2 net loss $12M ($20.91/shr), istaroxime data expected Q3 2024
------------------------------------------------------------------------

- Net loss of $12.0M ($20.91 per share) on 0.6M shares; operating loss $11.5M vs. $6.8M in Q2 2023.
- R&D expense $9.9M (incl. $7.5M non-cash Varian asset acquisition cost) vs. $1.8M; G&A $1.6M vs. $2.4M.
- Cash $1.8M, current liabilities $8.8M; substantial doubt about going concern disclosed.
- Closed July transactions for $13.9M gross proceeds ($4.4M new funding, $9.5M note extinguishment); $35M equity line secured.
- Istaroxime Phase 2 SEISMiC study enrollment near complete, topline by end of Q3 2024; board added Saundra Pelletier, Jed Latkin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774924027380/0001437749-24-027380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774924027380/wint20240529_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-027380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer